Development of A10P3C, an isoform-selective inhibitor of EGLN2, for targeting breast cancer.

A10P3C is a highly selective EGLN2 inhibitor that effectively suppresses breast cancer growth and progression with minimal toxicity.

• Why it matters: Targeting EGLN2 is crucial because it plays an oncogenic role in breast cancer, yet developing isoform-specific inhibitors has been challenging, limiting therapeutic options.
• What they did: Researchers used conformational sampling, ensemble docking, and simulation-based design to develop A10P3C, a small molecule with high potency and selectivity for EGLN2, tested in cell and animal models.
• The result: A10P3C inhibits breast cancer cell proliferation, migration, and invasion, induces cell cycle arrest and senescence, and demonstrates strong antitumor activity in patient-derived models, paving the way for precision therapies.